| 期刊簡介 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Current Atherosclerosis Reports LetPub Score 6.3
50 ratings
Rate
Reputation 7.6 Influence 5.2 Speed 7.0 | ||||||||||||||||
| 期刊簡稱 | CURR ATHEROSCLER REP | ||||||||||||||||
| ISSN | 1523-3804 | ||||||||||||||||
| E-ISSN | 1534-6242 | ||||||||||||||||
| h-index | 66 | ||||||||||||||||
| CiteScore |
| ||||||||||||||||
| 自引率 (2023-2024) | 3.50%自引率趨勢 | ||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||
| 官方網站 | https://www.springer.com/11883 | ||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/athe | ||||||||||||||||
| 開放訪問 | No | ||||||||||||||||
| 出版商 | Springer US | ||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||
| 出版國/地區 | US | ||||||||||||||||
| 發行頻率 | 隔月刊行 | ||||||||||||||||
| 創刊年 | 1999 | ||||||||||||||||
| 每年文章數 | 100每年文章數趨勢 | ||||||||||||||||
| 黃金OA百分比 | 30.69% | ||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q1
| ||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1523-3804%5BISSN%5D | ||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
| 競爭力 * | 來自作者的數據: Moderate | ||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Current Atherosclerosis Reports] 的評論 | 撰寫評論 |
| 作者: cigarrr 領域: 医学 審稿時間: 4.0 month(s) 結果: 修改後接受 撰寫評論 |
2026-06-07 18:44:55 評論於 The initial review is slow, taking 1 month. The external review is very slow, taking 3-4 months. However, the revision suggestions are relatively simple.  (0) 讚！ | cigarrr  |
| 作者: 宫古鸿羲 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2024-04-29 19:18:29 評論於 Review speed: 6.0 | Submission hit rate: 75.0 Research direction emphasis: Vascular surgery; Non-solicited review; Aortic aneurysm experience sharing: self-submitted review, delayed by editor for over three months, reviewers took about a month to review and accepted the submission (0) 讚！ | 宫古鸿羲 |
| 作者: 桃花彩萱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-04-13 10:01:49 評論於 Please translate the following paragraph into English and Japanese, and use ":" and ":" as headings (0) 讚！ | 桃花彩萱 |
| 作者: 残月元纬 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-09-16 12:58:57 評論於 Are all review articles commissioned? (0) 讚！ | 残月元纬 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 16:13:09 評論於 According to the requirements set by the journal's author guidelines, it should be uploaded (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 09:39:15 評論於 Due to the many factors that can affect the efficacy of animal experiments or clinical treatments, unless the results clearly show a synergistic effect greater than the sum of the effectiveness of each drug, it is generally referred to as an enhancing effect (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 21:18:16 評論於 How to determine whether two drugs have synergistic or additive effects? (0) 讚！ | Oswald Edie |
| 作者: 深渊兴业 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 16:29:04 評論於 Are there any requirements for submitting an article? (0) 讚！ | 深渊兴业 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-18 08:26:11 評論於 The past was fine, but the current downward trend is really scary. I hope to get back to the 3-point level next year, but it might be too difficult (0) 讚！ | 凌霄高洁 |
| 作者: 匿名 領域: 審稿時間: 0.0 month(s) 結果: 撰寫評論 |
2013-03-25 11:27:00 評論於 Influence factor 2.664 Still a good journal mainIt is the study of atherosclerosis that has recently been done as a pathway mechanism. So I paid attention to this journal (0) 讚！ | 匿名 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2012-11-28 23:24:47 評論於 Can we achieve a score of 3 points next year? Let's discuss (0) 讚！ | 凌霄高洁 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us